Precision Biosciences (DTIL) Receivables - Net (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Receivables - Net data on file, last reported at $4.0 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 99900.0% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 99900.0% increase from a year earlier, with the FY2024 full-year figure at $229000.0, down 74.58% from the prior year.
• Receivables - Net for Q1 2026 stood at $4.0 million, up from $4000.0 in the prior quarter.
• Over the last five years, Receivables - Net for DTIL reached as high as $50.5 million in Q2 2022 and fell as low as $4000.0 in Q1 2025.
• Historically, Receivables - Net has averaged $4.2 million across 5 years, with a median of $652000.0 in 2023.
• Across the five-year window, Receivables - Net sank 98.97% in 2025 and soared 99900.0% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $720000.0 in 2022, then gained by 25.14% to $901000.0 in 2023, then plunged by 74.58% to $229000.0 in 2024, then tumbled by 98.25% to $4000.0 in 2025, then surged by 99900.0% to $4.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $4.0 million in Q1 2026, $4000.0 in Q3 2025, and $4000.0 in Q1 2025.